OIPE
JUN 18 2001
PATENT & TRADEMARK OFFICE

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 210121.419C11	APPLICATION NO. 09/810,936
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Tony N. Frudakis et al.	
		FILING DATE March 16, 2001	GROUP ART UNIT 1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CDL	AA	5,872,237	02/16/99	Feder et al.	536	23.5	
CDL	AB	5,811,535	10/22/98	Adamou et al.	536	23.5	
CDL	AC	5,585,270	12/17/96	Grotendorst et al.	435	252.3	
CDL	AD	5,523,225	06/04/96	Kraus	435	240.1	
CDL	AE	5,516,650	05/14/96	Foster et al.	435	68.1	
CDL	AF	5,428,145	06/27/95	Okamoto et al.	536	23.72	
CDL	AG	5,231,012	07/27/93	Mosmann et al.	435	69.52	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO
CDL	AH	GB 2 273 099 A	06/08/94	Great Britain		
CDL	AI	WO 98/45328	10/15/98	WIPO		
CDL	AJ	WO 97/25431	07/17/97	WIPO		
CDL	AK	WO 97/25426	07/17/97	WIPO		
CDL	AL	WO 97/06256	02/20/97	WIPO		
CDL	AM	WO 96/38463	12/05/96	WIPO		
CDL	AN	WO 95/32311	11/30/95	WIPO		
CDL	AO	WO 95/19369	07/20/95	WIPO		
CDL	AP	WO 95/10777	04/20/95	WIPO		
CDL	AQ	WO 91/02062	02/21/91	WIPO		

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

CDL	AR		Adams et al., Genbank Accession No. Q60347, 1993.
CDL	AS		Adams et al., Genbank Accession No. Q61250, 1993.

EXAMINER	DATE CONSIDERED
	9/11/02

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

OIPE
JUN 18 2001
PATENT & TRADEMARK OFFICE

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 210121.419C11	APPLICATION NO. 09/810,936
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		APPLICANTS Tony N. Frudakis et al.	
		FILING DATE March 16, 2001	GROUP ART UNIT 1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO
CDL	BB	WO 94/11514	05/26/94	WIPO		
CDL	BC	2,044,940A1	12/11/92	Canada		
CDL	BD	WO 92/15680	09/17/92	WIPO		
CDL	BE	WO 92/10573	06/25/92	WIPO		
CDL	BF	EP0475623A1	03/18/92	Europe		

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

CDL	BG		Ahmed et al., "Characterization of a retrovirus isolated form normal mink cells co-cultivated with a dog mammary tumour," *J. Gen. Virol. 42*:179-184, 1979.
CDL	BH		Anderson et al., "Sequence and organization of the human mitochondrial genome," *Nature 290*:457-465, 1981.
CDL	BI		Bakker et al., "Generation of antimelanoma cytotoxic T lymphocytes for healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells *in vivo*," *Cancer Research 55*:5330-5334, November 15, 1995.
CDL	BJ		Bauer et al., "Identification of differentially expressed mRNA species by an improved display technique (DDRT-PCR)," *Nucleic Acids Research 21*(18):4272-4280, 1993.
CDL	BK		Bernard et al., "Cloning and Sequencing of Pro-α1(XI) Collagen cDNA Demonstrates That Type XI Belongs to the Fibrillar Class of Collagens and Reveals That the Expression of the Gene Is Not Restricted to Cartilagenous Tissue," *J. Biol. Chem. 263*(32):17159-17166, 1988.
CDL	BL		Bratthauer et al., "Expression of LINE-1 Retrotransposons in Human Breast Cancer," *Cancer 73*:2333-2336, 1994.
CDL	BM		Byrne et al., "A Screening Method to Identify Genes Commonly Overexpressed in Carcinomas and the Identification of a Novel Complementary DNA Sequence," *Cancer Research 55*:2869-2903, 1995.

EXAMINER	DATE CONSIDERED
	9/11/02

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

OIPE JUN 18 2001 PATENT & TRADEMARK OFFICE

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 210121.419C11	APPLICATION NO. 09/810,936
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Tony N. Frudakis et al.	
		FILING DATE March 16, 2001	GROUP ART UNIT 1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA						
	CB						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO
	CC					
	CD					

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

CM	CE		Cease et al., "T cell clones specific for an amphipathic a-helical region of sperm whale myoglobin show differing fine specificities for synthetic peptides," *Journal of Experimental Medicine 164*:1779-1784, November 1986.
CM	CF		Chai et al., Genbank Accession No. U03644, 1994.
CM	CG		Charnock-Jones et al., "Extension of incomplete cDNAs (ESTs) by biotin/streptavidin-mediated walking using polymerase chain reaction," *J. Biotechno. 35*:205-215, June 1994.
CM	CH		Chen and Sager, "Differential Expression of Human Tissue Factor in Normal Mammary Epithelial Cells and in Carcinomas," *Molecular Medicine 1*(2): 153-160, 1995.
CM	CI		Cordonnier et al., "Isolation of Novel Human Endogenous Retrovirus-Like Elements with Foamy Virus-Related *pol* Sequence," *Journal of Virology 69*(9):5890-5897, 1995.
CM	CJ		Databank Genebank Accession No. Z34289, 1995.
CM	CK		Derks et al., "Synthesis of a viral protein with molecular weight of 30,000 (p30) by leukemic cells and antibodies cross-reacting with simian sarcoma virus p30 in serum of a chronic myeloid leukemia patient," *Cancer Research 42*:681-686, February 1982.

EXAMINER	DATE CONSIDERED
	9/11/02

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

OIPE JC171 JUN 18 2001 PATENT & TRADEMARK OFFICE

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 210121.419C11	APPLICATION NO. 09/810,936
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		APPLICANTS Tony N. Frudakis et al.	
		FILING DATE March 16, 2001	GROUP ART UNIT 1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	DA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO
	DB					

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

CR	DC		Ezzell, "Cancer "Vaccines": An Idea Whose Time Has Come?," *The Journal of NIH Research 7*:46-49, 1995.
CR	DD		Frank et al., Genbank Accession No. Q70049, 1994.
CR	DE		Gura, "Systems for Identifying New Drugs Are Often Faulty," *Science 278*:1041-1042, 1997.
CR	DF		Haltmeier et al., "Identification of S71-Related Human Endogenous Retroviral Sequences with Full-Length *pol* Genes," *Virology 209*:550-560, 1995.
CR	DG		Hehlmann et al., "Detection and biochemical characterization of antigens in human leukemic sera that cross-react with primate C-type viral proteins (M 30,000)[1]," *Cancer Research 43*:392-399, January 1983.
CR	DH		Herbrink et al., "Detection of antibodies cross-reactive with type C RNA tumor viral p30 protein in human sera and exudate fluids," *Cancer Research 40*:166-173, January 1980.
CR	DI		Hillier et al., Genbank Accession No. H80165, 1995.
CR	DJ		Hillier et al., Genbank Accession No. R19532, 1995.

EXAMINER	DATE CONSIDERED
	9/11/02

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

OIPE
JUN 18 2001
PATENT & TRADEMARK OFFICE

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 210121.419C11	APPLICATION NO. 09/810,936
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Tony N. Frudakis et al.	
		FILING DATE March 16, 2001	GROUP ART UNIT 1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	EA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO
	EB					

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

CM	EC		Hillier et al., Genbank Accession No. R55637, 1995.
CM	ED		Hillier et al., Genbank Accession No. R60426, 1995.
CM	EE		Hillier et al., Genbank Accession No. T83348, 1995.
CM	EF		Hillier et al., Genbank Accession No. R35308, 1995.
CM	EG		Hopp, T., "Computer prediction of protein surface features and antigenic determinants," *Molecular Basis of Cancer* Part B: Macromolecular Recognition, Chemotherapy, and Immunology:367-377, 1985.
CM	EH		Jerabek et al., "Detection and immunochemical characterization of a primate type C retrovirus-related p30 protein in normal human placentas," *Proc. Natl. Acad. Sci. USA 81*:6501-6505, October 1984.
CM	EI		Kast et al., "Role of HLA-A motifs in identification of potential CTL epitopes in human papillmavirus type 16 E6 and E7 proteins," *J. Immunol. 152*:3904-3912, 1994.
CM	EJ		Kawakami et al., "Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression," *J. Immunol. 154*:3961-3968, 1995.

EXAMINER	DATE CONSIDERED
	9/11/02

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

OIPE JC171 JUN 18 2001 PATENT & TRADEMARK OFFICE

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 210121.419C11	APPLICATION NO. 09/810,936
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Tony N. Frudakis et al.	
		FILING DATE March 16, 2001	GROUP ART UNIT 1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	FA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	FB							

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

CDL	FC		Keydar et al., "Properties of retrovirus-like particles produced by a human breast carcinoma cell line: Immunological relationship with mouse mammary tumor virus proteins," *Proc. Natl. Acad. Sci.* USA 81:4188-92, 1984.
CDL	FD		Leib-Mösch and Seifarth, "Evolution and Biological Significance of Human Retroelements," *Virus Genes 11*(2/3):133-145, 1996.
CDL	FE		Leib-Mösch et al., "Endogenous Retroviral Elements in Human DNA," *Cancer Research 50*:5636s-5642s, 1994.
CDL	FF		Leib-Mösch et al., "Genomic Distribution and Transcription of Solitary HERV-K LTRs," *Genomics 18*:261-269, 1993.
CDL	FG		Liang et al., "Differential Display of Eukaryotic Messenger RNA by Means of the Polymerase Chain Reaction," *Science 257*:967-971, 1992.
CDL	FH		Maeda et al., "Serum antibody reacting with placental syncytiotrophoblast in sera of patients with autoimmune diseases – a possible relation to type C RNA retroviruses," *Clin. Exp. Immunol. 60*:645-653, 1985.
CDL	FI		Margalit et al., "Prediction of immunodominant helper T cell antigenic sites from the primary sequence," *The Journal of Immunology 138*(7):2213-2229, April 1, 1987.
CDL	FJ		Matsubara et al., Genbank Accession No. T24124, 1995.

EXAMINER	DATE CONSIDERED
	9/11/02

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

OIPE JUN 18 2001 PATENT & TRADEMARK OFFICE

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 210121.419C11	APPLICATION NO. 09/810,936
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Tony N. Frudakis et al.	
		FILING DATE March 16, 2001	GROUP ART UNIT 1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	GA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	GB							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CR	GC		McCombs, R., "Role of oncornaviruses in carcinoma of the prostate," *Cancer Treatment Reports 61*(2):131-132, March/April 1977.
CR	GD		Porter-Jordan and Lippman et al., "Overview of the biologic markers of breast cancer," *Breast Cancer 8*(1):73-100, February 1994.
CR	GE		Rammensee et al., "MHC ligands and peptide motifs: first listing," *Immunogenetics 41*:178-228, 1995.
CR	GF		Rothbard and Taylor, "A sequence pattern common to T cell epitopes," *The EMBO Journal 7*(1):93-100, January 1988.
CR	GG		Sette et al., "The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes," *J. Immunol. 153*:5586-5592, 1994.
CR	GH		Smith et al., "Expression of antigenic crossreactivity to RD114 p30 protein in a human fibrosarcoma cell line," *Proc. Natl. Acad. Sci. USA 74*(2):744-748, February 1977.
CR	GI		Spouge et al., "Strong conformational propensities enhance T cell antigenicity," *The Journal of Immunology 138*(1):204-212, January 1987.
CR	GJ		Tsai et al., "*In vitro* immunization and expansion of antigen-specific cytotoxic T-lymphocytes for adoptive immunotherapy using peptide pulsed dendritic cells," *Critical Reviews in Immunology 18*:65-75, 1998

EXAMINER	DATE CONSIDERED
	9/11/02

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

OIPE
JUN 18 2001
PATENT & TRADEMARK OFFICE

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 210121.419C11	APPLICATION NO. 09/810,936
INFORMATION DISCLOSURE STATEMENT (Several sheets if necessary)		APPLICANTS Tony N. Frudakis et al.	
		FILING DATE March 16, 2001	GROUP ART UNIT 1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	HA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	HB							

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

CDL	HC		Vaczi and Toth, "Studies on antigens of C-type primate viruses and antibodies to them at patients wit myeloid leukemia and potentially preleukemic hematological disorders," *Arch. Geschwulstforsch 50*(8):769-777, 1980.
CDL	HD		Visseren et al., "CTL specific for the tyrosinase autoantigen can be induced form healthy donor blood to lyse melanoma cells," *J. Immunol 154*:3991-3998, 1995.
CDL	HE		Vitiello et al., "Analysis of the HLA-restricted influenza specific cytotoxic T lymphcyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatability complex," *J. Exp. Med. 173*:1007-1015, April 1991.
CDL	HF		Wang et al., "Detection of Mammary Tumor Virus *ENV* Gene-like Sequences in Human Breast Cancer," *Cancer Research 55*:5173-5179, 1995.
CDL	HG		Watson and Fleming, "Isolation of Differentially Expressed Sequence Tags from Human Breast Cancer," *Cancer Research 54*(17):4598-4602, 1994.
CDL	HH		Werner et al., "S71 Is a Phylogenetically Distinct Human Endogenous Retroviral Element with Structural and Sequence Homology to Simian Sarcoma Virus (SSV)," *Virology 174*:225-238, 1990.
CDL	HI		Wiley and Cunningham, "A steady state model for analyzing the cellular binding, internalization and degradation of polypeptide ligands," *Cell 25*:433-440, August 1981.
CDL	HJ		Yoshioka et al., "Pro-α1(XI) Collagen. Structure Of The Amino-Terminal Propeptide And Expression Of The Gene In Tumor Cell Lines," *J. Biol. Chem. 265*(11):6423-6426, 1990.
CDL	HK		Critical Synergy: The Biotechnology Industry and Intellectual Property Protection, Presentation of the Intellectual Property Committee of the Biotechnology Industry Organization at the October 17, 1994, Hearing of the U.S. Patent and Trademark Office, San Diego, CA, published by the Biotechnology Industry Organization, Washington, D.C., pp. 75, 100-107.

EXAMINER	DATE CONSIDERED
	9/16/02

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

OIPE
JUN 18 2001
PATENT & TRADEMARK OFFICE

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 210121.419C11	APPLICATION NO. 09/810,936
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Tony N. Frudakis et al.	
		FILING DATE March 16, 2001	GROUP ART UNIT 1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	IA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	IB							

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

CM	IC		GenBank Accession No. Z34289, "H. sapiens mRNA for nucleolar phosphoprotein p130," June 1, 1995.
	ID		
	IE		
	IF		
	IG		
	IH		
	II		
	IJ		
	IK		

EXAMINER	DATE CONSIDERED
	9/11/02

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).